<SEC-DOCUMENT>0000950170-25-006473.txt : 20250117
<SEC-HEADER>0000950170-25-006473.hdr.sgml : 20250117
<ACCEPTANCE-DATETIME>20250117060229
ACCESSION NUMBER:		0000950170-25-006473
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250117

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sage Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001597553
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-88275
		FILM NUMBER:		25536894

	BUSINESS ADDRESS:	
		STREET 1:		55 CAMBRIDGE PARKWAY
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-299-8380

	MAIL ADDRESS:	
		STREET 1:		55 CAMBRIDGE PARKWAY
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BB BIOTECH AG
		CENTRAL INDEX KEY:			0000924223
		STANDARD INDUSTRIAL CLASSIFICATION:	UNKNOWN SIC - 0000 [0000]
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		SCHWERTSTRASSE 6
		CITY:			SCHAFFHAUSEN
		STATE:			V8
		ZIP:			8200
		BUSINESS PHONE:		411724 59 59

	MAIL ADDRESS:	
		STREET 1:		SCHWERTSTRASSE 6
		CITY:			SCHAFFHAUSEN
		STATE:			V8
		ZIP:			8200
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0001193125-23-042126</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0000924223</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>3</amendmentNo>
<securitiesClassTitle>Common Stock</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>01/13/2025</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001597553</issuerCik>
<issuerName>Sage Therapeutics, Inc.</issuerName>
<issuerCusip>78667J108</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<street1 xmlns="http://www.sec.gov/edgar/common">55 CAMBRIDGE PARKWAY</street1>
<city xmlns="http://www.sec.gov/edgar/common">CAMBRIDGE</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">02142</zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>
<reportingPersonName>BB Biotech AG</reportingPersonName>
<memberGroup>a</memberGroup>
<citizenshipOrOrganization>V8</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>1178503</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>1178503</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1178503</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>1.9</classPercent>
<typeOfReportingPerson>HC</typeOfReportingPerson>
<typeOfReportingPerson>CO</typeOfReportingPerson>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>
<reportingPersonName>Biotech Target N.V.</reportingPersonName>
<memberGroup>a</memberGroup>
<citizenshipOrOrganization>P8</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>1178503</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>1178503</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1178503</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>1.9</classPercent>
<typeOfReportingPerson>CO</typeOfReportingPerson>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Sage Therapeutics, Inc.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>215 First Street, Cambridge, MA 02141</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>BB Biotech AG ("BB Biotech") on behalf of its wholly-owned subsidiary, Biotech Target N.V. ("Biotech Target")</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland
Biotech Target N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curacao</principalBusinessOfficeOrResidenceAddress>
<citizenship>BB Biotech AG: Switzerland
Biotech Target N.V.: Curacao </citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>1,178,503</amountBeneficiallyOwned>
<classPercent>1.9%</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote> 0 </solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>1,178,503</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>1,178,503</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>N</notApplicableFlag>
<classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>N</notApplicableFlag>
<subsidiaryIdentificationAndClassification>This statement is filed jointly by BB Biotech and Biotech Target, Biotech Target is a wholly-owned subsidiary of BB Biotech.</subsidiaryIdentificationAndClassification>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11.

 </certifications>
</item10>
</items>
<exhibitInfo>Exhibit A: Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.*

 *Previously filed as an exhibit to BB Biotech AG and Biotech Target N.V.'s Schedule 13G filed with the Securities and Exchange Commission on February 17, 2023. </exhibitInfo>
<signatureInformation>
<reportingPersonName>BB Biotech AG</reportingPersonName>
<signatureDetails>
<signature>/s/ Martin Gubler</signature>
<title>Martin Gubler</title>
<date>01/16/2025</date>
</signatureDetails>
<signatureDetails>
<signature>/s/ Ivo Betschart</signature>
<title>Ivo Betschart</title>
<date>01/16/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Biotech Target N.V.</reportingPersonName>
<signatureDetails>
<signature>/s/ Jan Bootsma</signature>
<title>Jan Bootsma</title>
<date>01/16/2025</date>
</signatureDetails>
<signatureDetails>
<signature>/s/ Hugo van Neutegem</signature>
<title>Hugo van Neutegem</title>
<date>01/16/2025</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
